Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study
Conclusions24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Allergy & Immunology | Cardiology | Cardiovascular | Endocrinology | Heart | Orthopaedics | Osteoporosis | Reclast | Study | Women | Xgeva | Zometa